{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:20:45Z","timestamp":1792203645153,"version":"4.4.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the pharmacokinetic\/pharmacodynamic properties of once\u2010weekly insulin icodec in individuals with type 1 diabetes (T1D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In this randomized, open\u2010label, two\u2010period crossover trial, 66 individuals with T1D (age 18\u201364\u2009years; glycated haemoglobin \u226475\u2009mmol\/mol [\u2264\u20099%]) were to receive once\u2010weekly icodec (8\u2009weeks) and once\u2010daily insulin glargine U100 (2\u2009weeks) at individualized fixed equimolar total weekly doses established during up to 10\u2009weeks' run\u2010in with glargine U100 titrated to pre\u2010breakfast plasma glucose (PG) of 4.4\u20137.2\u2009mmol\/L (80\u2013130\u2009mg\/dL). Insulin aspart was used as bolus insulin. Blood sampling for icodec pharmacokinetics was performed from the first icodec dose until 35\u2009days after the last dose. The glucose infusion rate at steady state was assessed in glucose clamps (target 6.7\u2009mmol\/L [120\u2009mg\/dL]) at 16\u201352\u2009h and 138\u2013168\u2009h after the last icodec dose and 0\u201324\u2009h after the last glargine U100 dose. Icodec pharmacodynamics during 1\u2009week were predicted by pharmacokinetic\u2010pharmacodynamic modelling. Hypoglycaemia was recorded during the treatment periods based on self\u2010measured PG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Icodec reached pharmacokinetic steady state on average within 2\u20133\u2009weeks. At steady state, model\u2010predicted daily proportions of glucose infusion rate during the 1\u2010week dosing interval were 14.3%, 19.6%, 18.3%, 15.7%, 13.1%, 10.6% and 8.4%, respectively. Rates and duration of Level 2 hypoglycaemic episodes (PG\u2009&lt;3.0\u2009mmol\/L [54\u2009mg\/dL]) were 32.8 versus 23.9 episodes per participant\u2010year of exposure and 33\u2009\u00b1\u200925 versus 30\u2009\u00b1\u200918\u2009min (mean\u2009\u00b1\u2009SD) for icodec versus glargine U100.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The pharmacokinetic\/pharmacodynamic properties of icodec suggest its potential to provide basal coverage in a basal\u2010bolus insulin regimen in people with T1D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15510","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T21:24:31Z","timestamp":1708464271000},"page":"1941-1949","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacokinetic and pharmacodynamic properties of once\u2010weekly insulin icodec in individuals with type 1 diabetes"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0940-8972","authenticated-orcid":false,"given":"Ulrike","family":"H\u00f6velmann","sequence":"first","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Engberg","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8346-2037","authenticated-orcid":false,"given":"Tim","family":"Heise","sequence":"additional","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Rode","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"N\u00f8rgreen","sequence":"additional","affiliation":[{"name":"Novo Nordisk  Aalborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-5452","authenticated-orcid":false,"given":"Eric","family":"Zijlstra","sequence":"additional","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Ribel\u2010Madsen","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145721709345773"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221104142"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001329"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154924"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00257"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002301"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15266"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S002"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01243-6"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S006"},{"key":"e_1_2_9_13_1","volume-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Rowland M","year":"2011"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296815576957"},{"key":"e_1_2_9_15_1","unstructured":"EMA.Protaphane. Summary of Product Characteristics.2020Accessed January 26 2024https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/protaphane-epar-product-information_en.pdf"},{"key":"e_1_2_9_16_1","unstructured":"EMA.Levemir. Summary of Product Characteristics.2021Accessed January 26 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/levemir-epar-product-information_en.pdf"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1058779"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14956"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02179-7"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12703"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:51:54Z","timestamp":1761886314000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/dom.15510"],"URL":"https:\/\/doi.org\/10.1111\/dom.15510","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"2023-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}